FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285890> ?p ?o ?g. }

• W4379285890 endingPage "1106" @default.
• W4379285890 startingPage "1106" @default.
• W4379285890 abstract "1106 Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for HER2+ metastatic breast cancer (MBC) and HER2-low (IHC 1+ or 2+ with FISH-) MBC . Pneumonitis with T-DXd has been observed in 13.6% of patients (pts) on DESTINY-Breast 01 (including 2.2% fatal events) and 12.1% in pts on DESTINY-BREAST 04 (including 0.8% fatal events). There is an unmet need to determine if pts with baseline lung abnormalities are at increased risk for development of pneumonitis from T-DXd. Methods: This retrospective cohort study included all pts treated with T-DXd for MBC at an academic institution from 1/2020 to 2/2023 for more than 1 cycle (>21 days). Outcomes were evaluated from treatment initiation until 2/1/2023. Two board-certified radiologists blinded to outcomes reviewed staging chest CTs performed before initiating T-DXd and graded each scan on 16 parenchymal abnormalities, including presence of interstitial lung abnormalities (ILA). Pneumonitis was retrospectively adjudicated by an independent oncologist using chart review and graded according to CTCAE v5.0 and compared to the treating physician’s assessment. The difference of proportions was analyzed with the Pearson Chi-Square test. Significance was declared at the 0.05 type I error threshold. Results: A total of 68 pts (median age 57.3 years) were included (30 = HER2+, 24 = HR+/HER2 low, 14 = TNBC/HER2 low). By independent assessment, 16 pts (23.5%) had grade 1 pneumonitis and 3 pts (4.4%) grade 2 pneumonitis. Median time from treatment initiation to pneumonitis was 83 days (range 35-266). By treating physician assessment, 5 pts (7.4%) developed grade 1 pneumonitis and 3 pts (4.4%) developed grade 2 pneumonitis. 16 of 68 pts (23.5%) had baseline ILA and 62 pts (91.2%) had at least one other parenchymal abnormality. As assessed by an independent oncologist, of pts with baseline ILA (N = 16), 12.5% developed T-DXd related pneumonitis, compared to 32.7% of pts without pre-existing ILA (N=52), p=0.16. There was no statistical difference in T-DXd related pneumonitis assessed by treating physician between pts with baseline ILA (2/16 patients, 12.5%) compared to pts without baseline ILA (7/52 pts, 13.5%), p=0.68. Conclusions: In this study, presence of baseline ILA was not associated with subsequent pneumonitis from T-DXd. Notably, the rate of independently assessed pneumonitis was higher than treatment-attributed pneumonitis as defined by the treating physician. Further research is needed to validate these findings and define predictors of treatment-associated pneumonitis. [Table: see text]" @default.
• W4379285890 created "2023-06-05" @default.
• W4379285890 creator A5006042046 @default.
• W4379285890 creator A5010499238 @default.
• W4379285890 creator A5017550097 @default.
• W4379285890 creator A5018738915 @default.
• W4379285890 creator A5034972183 @default.
• W4379285890 creator A5036335426 @default.
• W4379285890 creator A5044662545 @default.
• W4379285890 creator A5052031831 @default.
• W4379285890 creator A5052735318 @default.
• W4379285890 creator A5058699521 @default.
• W4379285890 date "2023-06-01" @default.
• W4379285890 modified "2023-09-25" @default.
• W4379285890 title "Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis." @default.
• W4379285890 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1106" @default.
• W4379285890 hasPublicationYear "2023" @default.
• W4379285890 type Work @default.
• W4379285890 citedByCount "0" @default.
• W4379285890 crossrefType "journal-article" @default.
• W4379285890 hasAuthorship W4379285890A5006042046 @default.
• W4379285890 hasAuthorship W4379285890A5010499238 @default.
• W4379285890 hasAuthorship W4379285890A5017550097 @default.
• W4379285890 hasAuthorship W4379285890A5018738915 @default.
• W4379285890 hasAuthorship W4379285890A5034972183 @default.
• W4379285890 hasAuthorship W4379285890A5036335426 @default.
• W4379285890 hasAuthorship W4379285890A5044662545 @default.
• W4379285890 hasAuthorship W4379285890A5052031831 @default.
• W4379285890 hasAuthorship W4379285890A5052735318 @default.
• W4379285890 hasAuthorship W4379285890A5058699521 @default.
• W4379285890 hasConcept C121608353 @default.
• W4379285890 hasConcept C126322002 @default.
• W4379285890 hasConcept C141071460 @default.
• W4379285890 hasConcept C143998085 @default.
• W4379285890 hasConcept C2776256026 @default.
• W4379285890 hasConcept C2777714996 @default.
• W4379285890 hasConcept C2779524853 @default.
• W4379285890 hasConcept C2779786085 @default.
• W4379285890 hasConcept C530470458 @default.
• W4379285890 hasConcept C71924100 @default.
• W4379285890 hasConcept C90924648 @default.
• W4379285890 hasConceptScore W4379285890C121608353 @default.
• W4379285890 hasConceptScore W4379285890C126322002 @default.
• W4379285890 hasConceptScore W4379285890C141071460 @default.
• W4379285890 hasConceptScore W4379285890C143998085 @default.
• W4379285890 hasConceptScore W4379285890C2776256026 @default.
• W4379285890 hasConceptScore W4379285890C2777714996 @default.
• W4379285890 hasConceptScore W4379285890C2779524853 @default.
• W4379285890 hasConceptScore W4379285890C2779786085 @default.
• W4379285890 hasConceptScore W4379285890C530470458 @default.
• W4379285890 hasConceptScore W4379285890C71924100 @default.
• W4379285890 hasConceptScore W4379285890C90924648 @default.
• W4379285890 hasFunder F4320332161 @default.
• W4379285890 hasIssue "16_suppl" @default.
• W4379285890 hasLocation W43792858901 @default.
• W4379285890 hasOpenAccess W4379285890 @default.
• W4379285890 hasPrimaryLocation W43792858901 @default.
• W4379285890 hasRelatedWork W1722328147 @default.
• W4379285890 hasRelatedWork W2066747782 @default.
• W4379285890 hasRelatedWork W2560406314 @default.
• W4379285890 hasRelatedWork W2593475799 @default.
• W4379285890 hasRelatedWork W2627001382 @default.
• W4379285890 hasRelatedWork W2751941543 @default.
• W4379285890 hasRelatedWork W2896532861 @default.
• W4379285890 hasRelatedWork W2934076975 @default.
• W4379285890 hasRelatedWork W4242374293 @default.
• W4379285890 hasRelatedWork W2342209702 @default.
• W4379285890 hasVolume "41" @default.
• W4379285890 isParatext "false" @default.
• W4379285890 isRetracted "false" @default.
• W4379285890 workType "article" @default.